CYP2D6 deficiency, a factor in ecstasy related deaths?

This publication has 10 references indexed in Scilit:

• Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs
  Biochemical Pharmacology, 2000
• CYP2D6 phenotype ??? genotype relationships in African-Americans and Caucasians in Los Angeles
  Pharmacogenetics, 1998
• MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6
  Addiction Biology, 1998
• Places and patterns of drug use in the Scottish dance scene
  Addiction, 1996
• Places and patterns of drug use in the Scottish dance scene
  Addiction, 1996
• Pathology of deaths associated with "ecstasy" and "eve" misuse.
  Journal of Clinical Pathology, 1996
• Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
  Annals of the Rheumatic Diseases, 1996
• The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)
  Biochemical Pharmacology, 1994
• Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
  The Lancet, 1992
• Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes
  Pharmacogenetics, 1991